Polygenic Risk Score Added to Conventional Case Finding to Identify Undiagnosed Chronic Obstructive Pulmonary Disease.

IF 63.1 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Jama-Journal of the American Medical Association Pub Date : 2025-01-22 DOI:10.1001/jama.2024.24212
Jingzhou Zhang, Brian D Hobbs, Edwin K Silverman, David Sparrow, Victor E Ortega, Hanfei Xu, Chengyue Zhang, Josée Dupuis, Allan J Walkey, George T O'Connor, Michael H Cho, Matthew Moll
{"title":"Polygenic Risk Score Added to Conventional Case Finding to Identify Undiagnosed Chronic Obstructive Pulmonary Disease.","authors":"Jingzhou Zhang, Brian D Hobbs, Edwin K Silverman, David Sparrow, Victor E Ortega, Hanfei Xu, Chengyue Zhang, Josée Dupuis, Allan J Walkey, George T O'Connor, Michael H Cho, Matthew Moll","doi":"10.1001/jama.2024.24212","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Chronic obstructive pulmonary disease (COPD) is often undiagnosed. Although genetic risk plays a significant role in COPD susceptibility, its utility in guiding spirometry testing and identifying undiagnosed cases is unclear.</p><p><strong>Objective: </strong>To determine whether a COPD polygenic risk score (PRS) enhances the identification of undiagnosed COPD beyond a case-finding questionnaire (eg, the Lung Function Questionnaire) using conventional risk factors and respiratory symptoms.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional analysis of participants 35 years or older who reported no history of physician-diagnosed COPD was conducted using data from 2 observational studies: the community-based Framingham Heart Study (FHS) and the COPD-enriched Genetic Epidemiology of COPD (COPDGene) study.</p><p><strong>Exposures: </strong>Modified Lung Function Questionnaire (mLFQ) scores and COPD PRS.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was spirometry-defined moderate to severe COPD (forced expiratory volume in the first second of expiration/forced vital capacity [FEV1/FVC] <0.7 and FEV1 [percent predicted] <80%). The performance of logistic models was assessed using the PRS, mLFQ score, and PRS plus mLFQ score for predicting spirometry-defined COPD.</p><p><strong>Results: </strong>Among 3385 FHS participants (median age, 52.0 years; 45.9% male) and 4095 COPDGene participants (median age, 56.8 years; 55.5% male) who reported no history of COPD, 160 (4.7%) FHS and 775 (18.9%) COPDGene participants had spirometry-defined COPD. Adding the PRS to the mLFQ score significantly improved the area under the curve from 0.78 to 0.84 (P < .001) in FHS, 0.69 to 0.72 (P = .04) in COPDGene non-Hispanic African American, and 0.75 to 0.78 (P < .001) in COPDGene non-Hispanic White participants. At a risk threshold for spirometry referral of 10%, the addition of the PRS to the mLFQ score correctly reclassified 13.8% (95% CI, 6.6%-21.0%) of COPD cases in FHS, but not in COPDGene.</p><p><strong>Conclusions and relevance: </strong>A COPD PRS enhances the identification of undiagnosed COPD beyond a conventional case-finding approach in the general population. Further research is needed to assess its impact on COPD diagnosis and outcomes.</p>","PeriodicalId":54909,"journal":{"name":"Jama-Journal of the American Medical Association","volume":" ","pages":""},"PeriodicalIF":63.1000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jama-Journal of the American Medical Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jama.2024.24212","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Importance: Chronic obstructive pulmonary disease (COPD) is often undiagnosed. Although genetic risk plays a significant role in COPD susceptibility, its utility in guiding spirometry testing and identifying undiagnosed cases is unclear.

Objective: To determine whether a COPD polygenic risk score (PRS) enhances the identification of undiagnosed COPD beyond a case-finding questionnaire (eg, the Lung Function Questionnaire) using conventional risk factors and respiratory symptoms.

Design, setting, and participants: This cross-sectional analysis of participants 35 years or older who reported no history of physician-diagnosed COPD was conducted using data from 2 observational studies: the community-based Framingham Heart Study (FHS) and the COPD-enriched Genetic Epidemiology of COPD (COPDGene) study.

Exposures: Modified Lung Function Questionnaire (mLFQ) scores and COPD PRS.

Main outcomes and measures: The primary outcome was spirometry-defined moderate to severe COPD (forced expiratory volume in the first second of expiration/forced vital capacity [FEV1/FVC] <0.7 and FEV1 [percent predicted] <80%). The performance of logistic models was assessed using the PRS, mLFQ score, and PRS plus mLFQ score for predicting spirometry-defined COPD.

Results: Among 3385 FHS participants (median age, 52.0 years; 45.9% male) and 4095 COPDGene participants (median age, 56.8 years; 55.5% male) who reported no history of COPD, 160 (4.7%) FHS and 775 (18.9%) COPDGene participants had spirometry-defined COPD. Adding the PRS to the mLFQ score significantly improved the area under the curve from 0.78 to 0.84 (P < .001) in FHS, 0.69 to 0.72 (P = .04) in COPDGene non-Hispanic African American, and 0.75 to 0.78 (P < .001) in COPDGene non-Hispanic White participants. At a risk threshold for spirometry referral of 10%, the addition of the PRS to the mLFQ score correctly reclassified 13.8% (95% CI, 6.6%-21.0%) of COPD cases in FHS, but not in COPDGene.

Conclusions and relevance: A COPD PRS enhances the identification of undiagnosed COPD beyond a conventional case-finding approach in the general population. Further research is needed to assess its impact on COPD diagnosis and outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
将多基因风险评分添加到常规病例发现中以识别未确诊的慢性阻塞性肺疾病。
重要性:慢性阻塞性肺疾病(COPD)常常无法确诊。尽管遗传风险在COPD易感性中起着重要作用,但其在指导肺活量测定和识别未确诊病例方面的作用尚不清楚。目的:确定COPD多基因风险评分(PRS)是否比使用常规危险因素和呼吸道症状的病例调查问卷(如肺功能问卷)更能增强对未确诊COPD的识别。设计、环境和参与者:对35岁或以上无医生诊断COPD病史的参与者进行横断面分析,使用来自2项观察性研究的数据:基于社区的Framingham心脏研究(FHS)和COPD富集遗传流行病学(COPDGene)研究。暴露:改良肺功能问卷(mLFQ)评分和COPD PRS。主要结局和指标:主要结局是由肺活量测定定义的中重度COPD(呼气前一秒用力呼气量/用力肺活量[FEV1/FVC])结果:3385名FHS参与者(中位年龄52.0岁;45.9%男性)和4095名COPDGene参与者(中位年龄56.8岁;55.5%男性)无COPD病史,160名(4.7%)FHS参与者和775名(18.9%)COPDGene参与者患有肺活量测定定义的COPD。将PRS加入mLFQ评分显著提高曲线下面积,从0.78提高到0.84 (P)。结论和相关性:COPD PRS在普通人群中比传统的病例发现方法更能提高对未确诊COPD的识别。需要进一步的研究来评估其对COPD诊断和预后的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
48.20
自引率
0.90%
发文量
1569
审稿时长
2 months
期刊介绍: JAMA (Journal of the American Medical Association) is an international peer-reviewed general medical journal. It has been published continuously since 1883. JAMA is a member of the JAMA Network, which is a consortium of peer-reviewed general medical and specialty publications.
期刊最新文献
COVID-19 Tied to Long-Term Kidney Function Decline. FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea. FDA's "Healthy" Food Rule Updated for First Time in 30 Years. Flavored E-Cigarette Bans Might Increase Young Adults' Cigarette Smoking. Formula Shortage Boosted Breastfeeding in US.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1